Infect Chemother.  2017 Mar;49(1):57-61. 10.3947/ic.2017.49.1.57.

Establishment of Experimental Murine Peritonitis Model with Hog Gastric Mucin for Carbapenem-Resistant Gram-Negative Bacteria

• Park JY
• Park C
• Chun HS
• Byun JH
• Cho SY
• Lee DG

• KMID: 2375100
• DOI: http://doi.org/10.3947/ic.2017.49.1.57

Abstract

Animal models are essential to studies of infectious diseases. The use of mice to test bacterial infection has been extensively reported. However, methods applied to clinical isolates, particularly for carbapenem-resistant bacteria, must be tailored according to the infection models and bacteria used. In this study, we infected 6-week-old female BALB/c mice intraperitoneally with different strains of resistant bacteria plus 3% hog gastric mucin. This method was found to be efficient and readily applicable for investigation of carbapenem-resisant Gram-negative pathogens (e.g., Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii) detected in Korea.

Keyword

Laboratory animal models; Peritonitis; Drug resistance, Multidrug resistance; Gram-negative bacteria

MeSH Terms

Acinetobacter
Animals
Bacteria
Bacterial Infections
Communicable Diseases
Escherichia coli
Female
Gastric Mucins*
Gram-Negative Bacteria*
Humans
Klebsiella pneumoniae
Korea
Methods
Mice
Models, Animal
Peritonitis*
Pseudomonas aeruginosa
Gastric Mucins

Figure

• 

  Figure 1 Carbapenem-resistant Escherichia coli (EC-1), Klebsiella pneumoniae (KP-4), Pseudomonas aeruginosa (PA-3) and Acinetobacter baumannii (Aci_100087) with or without 3% hog gastric mucin. Results show that animals inoculated with strains without mucin treatment failed in infection for both mice species, whereas with mucin, infection was successfully induced 24 h after the experiment except for E. coli infection of ICR mice. 3% hog gastric mucin dissolved in phosphate-buffered saline was used as a negative control for each experimental group.

Reference

1. World health organization (WHO). Global action plan on antimicrobial resistance. Accessed 14 October 2016. Available at: http://www.who.int/antimicrobial-resistance/global-action-plan/en/.

2. Lee CS, Doi Y. Therapy of infections due to carbapenem-resistant Gram-negative pathogens. Infect Chemother. 2014; 46:149–164.

3. van Duin D, Kaye KS, Neuner EA, Bonomo RA. Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes. Diagn Microbiol Infect Dis. 2013; 75:115–120.

4. Lee HJ, Choi JK, Cho SY, Kim SH, Park SH, Choi SM, Lee DG, Choi JH, Yoo JH. Carbapenem-resistant Enterobacteriaceae: prevalence and risk factors in a single community-based hospital in Korea. Infect Chemother. 2016; 48:166–173.

5. Pan CY, Chen JC, Chen TL, Wu JL, Hui CF, Chen JY. Piscidin is highly active against carbapenem-resistant Acinetobacter baumannii and NDM-1-producing Klebsiella pneumoniae in a systemic septicaemia infection mouse model. Mar Drugs. 2015; 13:2287–2305.

6. Cao F, Wang X, Wang L, Li Z, Che J, Wang L, Li X, Cao Z, Zhang J, Jin L, Xu Y. Evaluation of the efficacy of a bacteriophage in the treatment of pneumonia induced by multidrug resistance Klebsiella pneumoniae in mice. Biomed Res Int. 2015; 2015:752930.

7. Aoki N, Tateba K, Kikuchi Y, Kimura S, Miyazaki C, Ishii Y, Tanabe Y, Gejyo F, Yamaguchi K. Efficacy of colistin combination therapy in a mouse model of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa . J Antimicrob Chemother. 2009; 63:534–542.

8. Pan CY, Chen JC, Sheen JF, Lin TL, Chen JY. Epinecidin-1 has immunomodulatory effects, facilitating its therapeutic use in a mouse model of Pseudomonas aeruginosa sepsis. Antimicrob Agents Chemother. 2014; 58:4264–4274.

9. Harris G, Kuo Lee R, Lam CK, Kanzaki G, Patel GB, Xu HH, Chen W. A mouse model of Acinetobacter baumannii–associated pneumonia using a clinically isolated hypervirulent strain. Antimicrob Agents Chemother. 2013; 57:3601–3613.

10. Rosen DA, Hilliard JK, Tiemann KM, Todd EM, Morley SC, Hunstad DA. Klebsiella pneumoniae FimK promotes virulence in murine pneumonia. J Infect Dis. 2016; 213:649–658.

11. He S, He H, Chen Y, Wang W, Yu D. In vitro and in vivo analysis of antimicrobial agents alone and in combination against multi-drug resistant Acinetobacter baumannii . Front Microbiol. 2015; 6:507.

12. Luo G, Spellberg B, Gebremariam T, Bolaris M, Lee H, Fu Y, French SW, Ibrahim AS. Diabetic murine models for Acinetobacter baumannii infection. J Antimicrob Chemother. 2012; 67:1439–1445.

13. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing: Twenty-fifth informational supplement M100-S25. Wayne, PA: CLSI;2015.

14. Kim SH, Park C, Chun HS, Lee DG, Choi JK, Lee HJ, Cho SY, Park SH, Choi SM, Choi JH, Yoo JH. Pilot screening to determine antimicrobial synergies in a multidrug-resistant bacterial strain library. Microb Drug Resist. 2016; 22:372–378.

15. Division of laboratory animal resources (DLAR). Commonoly used mouse strains. Accessed 26 August 2016. Available at: https://www.research.uky.edu/dlar/documents/CommonMouseResearchModels.pdf.

16. Olitzki L. Mucin as a resistance-lowering substance. Bacteriol Rev. 1948; 12:149–172.

17. Dewitt CW. Differential effect of hog gastric mucin on properdin and host resistance to infection. J Bacteriol. 1958; 76:631–639.

18. Rodriguez CA, Aqudelo M, Gonzalez JM, Vesga O, Zuluaga AF. An optimized mouse thigh infection model for enterococci and its impact on antimicrobial phamacodynamics. Antimicrob Agents Chemother. 2015; 59:233–238.

19. Fattom AI, Sarwar J, Ortiz A, Naso R. A Staphylococcus aureus capsular polysaccharide (CP) vaccine and CP-specific antibodies protect mice against bacterial challenge. Infect Immun. 1996; 64:1659–1665.